Zhao Xuesen

Zhao Xuesen

Professor

Doctoral Supervisor (Capital Medical University)

Master’s Supervisor (Capital Medical University, Peking University Health Science Center)

Academic Appointments:

Oct. 2023 – Present: Standing Committee Member, Infectious Diseases Specialty Committee, Beijing Research Association for Chronic Disease Control and Health Education

Academic Journal Appointment:

Young Editorial Board Member, Infectious Diseases & Immunity

Research Focus:

Immune responses to viral infection

Education and Work Experience：

Education

Sep. 1992 – Jul. 1997, Peking University Health Science Center, Clinical Laboratory Science, Bachelor of Medicine

Sep. 2000 – Jul. 2003, Peking University Health Science Center, Department of Pathogen Biology, Master’s Degree in Molecular Virology

May 2005 – Nov. 2010, McMaster University, Hamilton, Ontario, Canada Ph.D. in Viral Infection and Immunity Work Experience

Sep. 1997 – Aug. 2000, Department of Pathogen Biology, Peking University Health Science Center, Teaching Assistant (Medical Microbiology)

Feb. 2011 – Jun. 2013, Drexel University College of Medicine, Philadelphia, PA, USA Postdoctoral Fellow, Molecular Virology and Immunology

Jul. 2013 – Apr. 2015, Baruch S. Blumberg Institute, Doylestown, PA, USA Postdoctoral Fellow, Molecular Virology and Immunology

May 2015 – Nov. 2020, Institute for Infectious Diseases, Beijing Ditan Hospital, Capital Medical University, Associate Researcher

Dec. 2015 – Jun. 2021, Institute for Infectious Diseases, Beijing Ditan Hospital, Capital Medical University, Associate Professor and Master’s Supervisor

Nov. 2020 – Present, Institute for Infectious Diseases, Beijing Ditan Hospital, Capital Medical University, Researcher, Professor, and Doctoral Supervisor

Selected Publications:

1. Danying Chen#, Xinglin Li#, Xiaohua Hao#, Yaruo Qiu#, Yanjun Song, Hui Sun, Yongmei Liu, Juan Du, Yuanyuan Zhang, Fan Xiao, Chuan Song, Yonghong Yan, Rui Song, Xi Wang*, Xuesen Zhao*, Ronghua Jin*. Reduced neutralization and Fc effector function to Omicron subvariants in sera from SARS-CoV-1 survivors after two doses of CoronaVac plus one dose subunit vaccine. J Med Virol. 2023 Oct;95(10):e29136. doi: 10.1002/jmv.29136. PMID: 37804496.(影响因子：12.7)  (Impact Factor: 12.7)

2. Yongmei Liu#, Danying Chen#, Yuanyuan Wang#, Xinglin Li, Yaruo Qiu, Mei Zheng, Yanjun Song, Guoli Li, Chuan Song, Tingting Liu, Yuanyuan Zhang, Ju-Tao Guo, Hanxin Lin*, Xuesen Zhao*.  Characterization of CCoV-HuPn-2018 spike protein-mediated viral entry. J Virol. 2023 Sep 7: e0060123. doi: 10.1128/jvi.00601-23. PMID: 37676001. (影响因子：5.4) (Impact Factor: 5.4)

3. Xuesen Zhao*, Danying Chen, Xinglin Li, Lauren Griffith, Jinhong Chang, Ping An, Ju-Tao Guo* (2022) Interferon Control of Human Coronavirus Infection and Viral Evasion: Mechanistic Insights and Implications for Antiviral Drug and Vaccine Development. J Mol Biol. 2022 Jan 3:167438. doi: 10.1016/j.jmb.2021.167438. (影响因子：6.15)(Impact Factor: 6.15) 

4. Xuesen Zhao# *, Danying Chen#, Robert Szabla, Mei Zheng, Guoli Li, Pengcheng Du, Shuangli Zheng, Xinglin Li, Chuan Song, Rui Li, Ju-Tao Guo, Murray Junop, Hui Zeng, Hanxin Lin* (2020). Broad and Differential Animal Angiotensin-Converting Enzyme 2 Receptor Usage by SARS-CoV-2. J Virol. 2020 Aug 31;94(18):e00940-20. doi: 10.1128/JVI.00940-20. (Top 5 cited article) (影响因子：5.1)(Impact Factor: 5.1) 

5. Xuesen Zhao# *, Shuangli, Zheng#, Danying Chen#, Mei Zheng, Xinglin Li, Guoli Li, Hanxin Lin, Jinhong Chang, Hui Zeng, Ju-Tao Guo* (2020). LY6E Restricts Entry of Human Coronaviruses, Including Currently Pandemic SARS-CoV-2. J Virol. 2020 Aug 31;94(18):e00562-20. doi: 10.1128/JVI.00562-20. (spotlight article) (影响因子：5.1)(Impact Factor: 5.1) 

6. Zheng Mei#, Zhao Xuesen# *, Zheng Shuangli#, Chen Danying#., Du Pengcheng, Li Xinglin, Jiang Dong, Guo Ju-Tao, Zeng Hui*, Lin Hanxin*(2020). Bat SARS-Like WIV1 coronavirus uses the ACE2 of multiple animal species as receptor and evades IFITM3 restriction via TMPRSS2 activation of membrane fusion. Emerg Microbes Infect, undefined(undefined), 1-36. doi:10.1080/22221751.2020.1787797 (影响因子：7.16)(Impact Factor: 7.16) 

7. Chen Danying#, Hou Zhifei#, Jiang Dong#., Zheng Mei#, Li Guoli, Zhang Yue, Li Rui., Lin Hanxin., Chang Jinhong., Zeng Hui., Guo Ju-Tao*, Zhao Xuesen*(2019). GILT restricts the cellular entry mediated by the envelope glycoproteins of SARS-CoV, Ebola virus and Lassa fever virus. Emerg Microbes Infect, 8(1), 1511-1523. doi:10.1080/22221751.2019.1677446 (影响因子：5.77)(Impact Factor: 5.77) 

8. Zhao Xuesen*, Sehgal Mohit, Hou Zhifei, Cheng Junjun, Shu Sainan, Wu Shuo, Guo Fang, Le Marchand Sylvain J, Lin Hanxin, Chang Jinhong, Guo Ju-Tao*. (2018). Identification of Residues Controlling Restriction versus Enhancing Activities of IFITM Proteins on Entry of Human Coronaviruses. J. Virol., 92(6), doi:10.1128/JVI.01535-17    (影响因子：4.3)(Impact Factor: 4.3) 

9. Xuesen Zhao, Fang Guo, Mary Ann Comunale, Anand Mehta, MohitSehgal, PoojaJain, Andrea Cuconati, Timothy M. Block, Jinhong Chang and Ju-Tao Guo* (2015) Inhibition of ER glucosidases impairs SARS-CoV and HCoV-NL63 spike protein-mediated entry by altering the glycan processing of ACE2. Antimicrob Agents Chemother 59:206-216.   (影响因子：4.4)(Impact Factor: 4.4) 

10. Xuesen Zhao, Fang Guo, Fei Liu, Andrea Cuconati, Jinhong Chang, Timothy M. Block and Ju-Tao Guo*. (2014) Interferon induction of IFITM proteins promotes infection by human coronavirus OC43. Proc Natl Acad Sci U S A. 111(18):6756-6761  (影响因子：9.8)(Impact Factor: 9.8) 

Awards and Honors

2016: 11th Cohort of the Beijing “Haiju” Talent Program (Full-Time Category)

2016: Selected for the Beijing Municipal “Hundred-Thousand-Talent Project” 

Contact Information:

Email: zhaoxuesen@ccmu.edu.cn

Work Phone: 010-84322612